Assurant vs AstraZeneca: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Assurant and AstraZeneca side by side

1. 1892Assurant

   La Crosse Mutual Aid Association formed

   Assurant traces its history to the La Crosse Mutual Aid Association, established in La Crosse, Wisconsin in 1892 to provide consumers with disability insurance. No founder of the association is named in the company own histories.

2. 1910Assurant

   Licensed as Time Insurance Company

   The Wisconsin Office of the Commissioner of Insurance records Time Insurance Company, the successor to the La Crosse Mutual Aid Association, as originally licensed as an insurer in 1910.

3. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

4. 1978Assurant

   N.V. AMEV of the Netherlands buys Time Insurance

   Dutch insurer N.V. AMEV acquired Time Insurance Company through its US holding company, AMEV Holdings, Inc., then expanded it by buying American Security Insurance, United Family, Western Insurance Company and Superior Insurance over the next 12 years.

5. 1991Assurant

   AMEV Holdings renamed Fortis, Inc.

   After AMEV combined with VSB Groep NV in 1990 to create Fortis, the US holding company AMEV Holdings, Inc. was rebranded Fortis, Inc. in 1991. It acquired John Alden in 1998.

6. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

7. 1999Assurant

   Fortis acquires American Bankers Insurance

   Fortis, Inc. bought American Bankers Insurance Group of Miami, adding credit insurance and specialty warranty underwriting that became the core of the modern specialty lines. Fortis sold its life insurance business to The Hartford in 2001.

8. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

9. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

10. 2004Assurant

    NYSE listing as Assurant, Inc.

    Fortis took the US business public on February 5, 2004 in a $1.76 billion initial public offering, the fourth largest of that year, and renamed it Assurant, Inc. The company was incorporated as a Delaware corporation in 2004 and trades as AIZ.

11. 2006Assurant

    Robert B. Pollock succeeds J. Kerry Clayton as CEO

    Founding chief executive J. Kerry Clayton retired on March 17, 2006 and was succeeded by Robert B. Pollock, then president and chief operating officer, who also joined the board that day.

12. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

13. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

14. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

15. 2013Assurant

    New York consent order on force-placed insurance

    Assurant, American Security Insurance Company and American Bankers Insurance Company of Florida settled a New York Department of Financial Services investigation into force-placed homeowners insurance on March 21, 2013, paying a $14 million penalty plus homeow…

16. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

17. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

18. 2015Assurant

    Exit from health insurance and employee benefits

    On June 10, 2015 Assurant announced it would leave the health insurance marketplace and wind down Assurant Health, and on September 9, 2015 it agreed to sell its employee benefits business to Sun Life for $940 million.

19. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

20. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

21. 2018Assurant

    The Warranty Group acquisition closes

    Assurant completed its purchase of The Warranty Group from TPG Capital on May 31, 2018 for a total enterprise value of about $2.5 billion, expanding vehicle service contracts and international retail protection. Assurant also sold Time Insurance in 2018.

22. 2020Assurant

    HYLA Mobile acquisition closes

    Assurant closed its acquisition of smartphone trade-in and upgrade provider HYLA Mobile on December 1, 2020, in a transaction the company valued at about $325 million, roughly doubling its device processing volumes.

23. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

24. 2021Assurant

    Global Preneed sold to CUNA Mutual Group

    Assurant closed the sale of its prearranged funeral and final expense business to CUNA Mutual Group on August 2, 2021 for about $1.35 billion, generating roughly $1.2 billion of net proceeds, and said it intended to return about $900 million of that through sh…

25. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

26. 2022Assurant

    Keith Demmings becomes CEO and headquarters moves to Atlanta

    Keith W. Demmings became president and chief executive officer in January 2022, succeeding Alan B. Colberg, who retired at the end of 2021 after seven years in the role.

27. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

28. 2024Assurant

    iSmash acquired in the United Kingdom

    Assurant acquired UK tech repair retailer iSmash on April 4, 2024, giving it 68 drop-in repair locations in the UK under the iSmash and Pocket Geek Tech Repair banners. Assurant also sold its mainland China operations during 2024.

29. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

30. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

31. 2025Assurant

    FY2025 revenue of $12.81B and the OptoFidelity purchase

    Assurant reported FY2025 revenue of $12.81 billion and GAAP net income of $872.7 million, its ninth consecutive year of profitable growth, launched Assurant Home Warranty, and in October 2025 acquired OptoFidelity mobile device test automation portfolio to add…

32. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

33. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

34. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

35. 2026Assurant

    RL Circular Operations acquired in Australia and New Zealand

    In January 2026 Assurant acquired RL Circular Operations, formerly TIC Reverse Logistics, the reverse logistics division of Australia and New Zealand based TIC Group, extending its post-purchase and circular economy capabilities across Asia Pacific.

36. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

37. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

38. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about Assurant vs AstraZeneca